Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence
暂无分享,去创建一个
K. Yamashita | H. Moriya | N. Katada | C. Katada | K. Hosoda | H. Mieno | M. Sugawara | Shoko Komori | M. Watanabe